Correlation of PD-L1 expression with toxicities and response
in oropharyngeal cancers treated with definitive chemoradiotherapy

Smriti Srivastava; Madhup Rastogi; Ajeet Gandhi; Rohini Khurana; Rahat Hadi; Shantanu Sapru; Anoop Srivastava; Avinav Bharati; Nuzhat Husain; Surendra Mishra; Kamal Sahni

doi:10.5114/wo.2022.118227

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2022
vol. 26

Send email

Copy url:

abstract:

Original paper

Correlation of PD-L1 expression with toxicities and response in oropharyngeal cancers treated with definitive chemoradiotherapy

Smriti Srivastava

¹

,

Madhup Rastogi

¹

,

Ajeet Kumar Gandhi

¹

,

Rohini Khurana

¹

,

Rahat Hadi

¹

,

Shantanu Sapru

¹

,

Anoop Srivastava

²

,

Avinav Bharati

²

,

Nuzhat Husain

³

,

Surendra Prasad Mishra

²

,

Kamal Sahni

¹

Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
Medical Physics, Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
Department of Pathology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India

Contemp Oncol (Pozn) 2022; 26: 180–186

DOI: https://doi.org/10.5114/wo.2022.118227

Online publish date: 2022/09/07

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Srivastava S, Rastogi M, Gandhi AK, et al. Correlation of PD-L1 expression with toxicities and response
in oropharyngeal cancers treated with definitive chemoradiotherapy. Contemporary Oncology/Współczesna Onkologia. 2022;26(3):180-186. doi:10.5114/wo.2022.118227.

APA

Srivastava, S., Rastogi, M., Gandhi, A. K., Khurana, R., Hadi, R.,  & Sapru, S. et al. (2022). Correlation of PD-L1 expression with toxicities and response
in oropharyngeal cancers treated with definitive chemoradiotherapy. Contemporary Oncology/Współczesna Onkologia, 26(3), 180-186. https://doi.org/10.5114/wo.2022.118227

Chicago

Srivastava, Smriti, Madhup Rastogi, Ajeet K Gandhi, Rohini Khurana, Rahat Hadi, Shantanu Sapru,  and Anoop Srivastava et al. 2022. "Correlation of PD-L1 expression with toxicities and response
in oropharyngeal cancers treated with definitive chemoradiotherapy". Contemporary Oncology/Współczesna Onkologia 26 (3): 180-186. doi:10.5114/wo.2022.118227.

Harvard

Srivastava, S., Rastogi, M., Gandhi, A., Khurana, R., Hadi, R., Sapru, S., Srivastava, A., Bharati, A., Husain, N., Mishra, S.,  and Sahni, K. (2022). Correlation of PD-L1 expression with toxicities and response
in oropharyngeal cancers treated with definitive chemoradiotherapy. Contemporary Oncology/Współczesna Onkologia, 26(3), pp.180-186. https://doi.org/10.5114/wo.2022.118227

MLA

Srivastava, Smriti et al. "Correlation of PD-L1 expression with toxicities and response
in oropharyngeal cancers treated with definitive chemoradiotherapy." Contemporary Oncology/Współczesna Onkologia, vol. 26, no. 3, 2022, pp. 180-186. doi:10.5114/wo.2022.118227.

Vancouver

Srivastava S, Rastogi M, Gandhi A, Khurana R, Hadi R, Sapru S et al. Correlation of PD-L1 expression with toxicities and response
in oropharyngeal cancers treated with definitive chemoradiotherapy. Contemporary Oncology/Współczesna Onkologia. 2022;26(3):180-186. doi:10.5114/wo.2022.118227.

PlumX metrics:

Introduction
The programmed death receptor ligand 1 (PD-L1) is a cell-surface glycoprotein expressed in tumour cells (TCs) and is also upregulated in tumour infiltrating lymphocytes. The effect of PD-L1 expression on TCs and tumour-infiltrating lymphocytes (TILs) on acute radiation toxicity and response in oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy is less known.

Material and methods
Squamous cell carcinoma of oropharynx with stage II-IVA (AJCC 8th) were recruited in this prospective observational study. Definitive radiation therapy (RT) of 70 Gray in 35 fractions at 2 Gray per fraction, 5 fractions a week in 2 phases was delivered with concurrent chemotherapy (cisplatin 40 mg/m2 weekly). Patients were assessed weekly for acute toxicities with Radiation Therapy Oncology Group criteria. Response assessment was done at 3 months post RT according to World Health Organization response assessment criteria. The programmed death receptor ligand 1 expression in TCs and TILs was correlated with acute toxicity and survival.

Results
Of 51 patients, 20 (39.2%) had PD-L1 expression in TCs and 18 (35.3%) in TILs. Patients with PD-L1 expression in TCs had fewer grade ≥ 3 oral mucositis (25% vs. 58%; p = 0.02) and grade ≥ 3 dysphagia (25% vs. 55%; p = 0.046). The programmed death receptor ligand 1-tumour infiltrating lymphocytes positives had lower ≥ 3 grade oral mucositis (22% vs. 58%; p = 0.02) and ≥ 3 grade dysphagia (17% vs. 58%; p = 0.007). Two-year overall and progression-free survival rate for the PD-L1-tumour-positive vs. PD-L1-tumour-negative group was not different (p > 0.5).

Conclusions
Positive PD-L1 expression is associated with fewer acute radiation toxicities, and this could be used as a potential biomarker.

keywords:

Correlation of PD-L1 expression with toxicities and response in oropharyngeal cancers treated with definitive chemoradiotherapy

Smriti Srivastava 1 , Madhup Rastogi 1 , Ajeet Kumar Gandhi 1 , Rohini Khurana 1 , Rahat Hadi 1 , Shantanu Sapru 1 , Anoop Srivastava 2 , Avinav Bharati 2 , Nuzhat Husain 3 , Surendra Prasad Mishra 2 , Kamal Sahni 1

radiotherapy, oropharyngeal cancer, PD-L1, toxicity, response

Smriti Srivastava

¹

,

Madhup Rastogi

¹

,

Ajeet Kumar Gandhi

¹

,

Rohini Khurana

¹

,

Rahat Hadi

¹

,

Shantanu Sapru

¹

,

Anoop Srivastava

²

,

Avinav Bharati

²

,

Nuzhat Husain

³

,

Surendra Prasad Mishra

²

,

Kamal Sahni

¹